| FSE

December 08, 2021 |
Bad Homburg, Germany

Credit Suisse – 10th Annual December Bus Tour

Presentation Import (ICS)

Download

All | None

Download

Related Links

Interactive Tool

FAQ

Frequently asked questions and Information on Fresenius SE & Co. KGaA

Usage of Alternative Performance Measures

The Fresenius Group uses alternative performance measures in its regulatory and mandatory publications that may represent so called non-GAAP-measures. These indicators are neither defined by US-GAAP nor by IFRS.

Within the internal control system of Fresenius non-GAAP-measures are used as key performance indicators.

The use of non-GAAP-measures for evaluating assets, financial and earnings position of Fresenius is not recommended on an isolated basis or as an alternative to the key performance indicators provided within the consolidated financial statements prepared in accordance with US-GAAP and IFRS.

The non-GAAP-measures used are listed and explained below:

In order to measure the operating performance extending over several periods, key performance measures are “adjusted“ where applicable.

Adjustments may arise from acquisitions/divestitures or the adoption of new accounting standards. Reconciliation tables are available within the respective quarterly or annual report and present the composition of adjustments.

EBIT does include depreciation and write-ups on property, plant and equipment.

EBIT is calculated by subtracting cost of sales, selling, general and administrative expenses and research and development expenses from sales.

EBIT margin is calculated as the ratio of EBIT to sales.

EBITDA is calculated from EBIT by adding depreciations recognized in income and deducting write-ups recognized in income, both, on intangible assets as well as property, plant and equipment.

EBITDA margin is calculated as the ratio of EBITDA to sales.

Financial key figure that shows the net balance of incoming and outgoing payments during a reporting period.

Operating cash flow is a financial measure showing cash inflows from operating activities during a period. Operating cash flow is calculated by subtracting non-cash income and adding non-cash expenses to net income.

Cash flow from investing activities is a financial measure opposing payments for the acquisition or purchase of property, plant and equipment and investments versus proceeds from the sale of property, plant and equipment and investments.

Cash flow from financing activities is a financial measure showing how the investments of the reporting period were financed.

Cash flow from financing activities is calculated from additions to equity plus proceeds from the exercise of stock options less dividends paid plus proceeds from debt increase (loans, bonds, senior notes, etc.) less repayments of debt plus the change in noncontrolling interest plus proceeds from the hedge of exchange rate effects due to corporate financing.

Fresenius uses the cash flow before acquisitions and dividends as the financial measure for free cash flow. Cash flow before acquisitions and dividends is calculated by operating cash flow less investments (net). Net investments are calculated by payments for the purchase of property, plant and equipment less proceeds from the sale of property, plant and equipment.

The cash conversion rate is defined as the ratio of adjusted free cash flow (cash flow before acquisitions and dividends; before interest, tax and special items) to operating income (EBIT) before special items. This allows us to assess our ability to generate cash and amongst others, also to pay dividends.

Net debt/EBITDA is a financial measure reflecting the ability of Fresenius to fulfill its payment obligations. Net debt and EBITDA are calculated at LTM (last twelve month) average exchange rates respectively.

Calculation of net debt:
Short-term debt
+ Short-term debt from related parties
+ Current portion of long-term debt and capital lease obligations
+ Current portion of Senior Notes
+ Long-term debt and capital lease obligations, less current portion
+ Senior Notes, less current portion
+ Convertible bonds
= Debt
- less cash and cash equivalents
= Net debt

Indicates the average number of days it takes for a receivable to be paid.

Growth that is generated by a company’s existing businesses and not by acquisitions, divestitures, or foreign exchange impact.

Constant currencies for income and expenses are calculated using prior year average rates; constant currencies for assets and liabilities are calculated using the mid-closing rate on the date of the respective statement of financial position.

Measure of a corporation’s profitability revealing how much profit a company generates
with the money shareholders have invested. ROE is calculated by fiscal year’s net income / total equity x 100.

Calculated by: (EBIT - taxes) / Invested capital

Invested capital = total assets + amortization of goodwill (accumulated) - deferred tax assets - cash and cash equivalents - trade accounts payable - accruals (without pension accruals) - other liabilities not bearing interest

Reconciliation of average invested capital and ROIC

€ in millions, except for ROIC	31.12.2021	31.12.2020
Total assets	71,962	66,646
Plus: Cumulative goodwill amortization	719	690
Minus: Cash and cash equivalents	- 2,764	- 1,837
Minus: Loans to related parties	- 63	- 62
Minus: Deferred tax assets	-858	-812
Minus: Accounts payable	- 2,039	- 1,816
Minus: Accounts payable to related parties	- 92	- 67
Minus: Provisions and other current liabilities¹	- 8,925	- 8,649
Minus: Income tax payable	- 495	- 504
Invested Capital	57,445	53,589
Average invested capital as of December 31, 2021 / 2020²	55,893	54,648
Operating income^3,4	4,260	4,614
Income tax expense	- 964	- 1,065
NOPAT^3,4	3,296	3,549
ROIC in %	5.9 %	6.5 %

¹ Includes non-current provisions and payments outstanding for acquisition; does not include pension liabilities and noncontrolling interest subject to put provisions.
² Includes adjustments for acquisitions in the respective reporting period with a purchase price above a certain level
(2021: € 752 million; 2020: € 220 million).
³Includes adjustments for acquisitions in the respective reporting period with a purchase price above a certain level
(2021: € 8 million; 2020: € 2 million).
⁴ Before special items

Calculated as the ratio of EBIT to operating assets (average).

Operating assets = total assets - deferred tax assets - trade accounts payable - cash held in trust - payments received on account - approved subsidies

Reconciliation of average operating assets and ROOA

€ in millions, except for ROOA	31.12.2021	31.12.2020
Total assets	71,962	66,646
Minus: Contract liabilities	- 535	- 962
Minus: Payments received on account	0	0
Minus: Cash held in trust	- 154	- 121
Minus: Loans to related parties	- 63	- 62
Minus: Deferred tax assets	- 858	- 812
Minus: Accounts payable	- 2,039	- 1,816
Minus: Accounts payable to related parties	- 92	- 67
Minus: Approved subsidies due to Hospital Funding Act („Krankenhausfinanzierungsgesetz“, KHG)	- 118	- 82
Operating assets	68,103	62,724
Average operating assets as of December 31, 2021 / 2020¹	65,384	62,976
Operating income^2,3	4,260	4,614
ROOA in %	6.5 %	7.3 %

¹ Includes adjustments for acquisitions in the respective reporting period with a purchase price above a certain level
(2021: € 868 million; 2020: € 346 million).
² Includes adjustments for acquisitions in the respective reporting period with a purchase price above a certain level
(2021: € 8 million; 2020: € 2 million).
³ Before special items

Indicates the average number of days between receiving goods as inventory and the sale of the finished product.

Calculated by: (Inventories / Costs of goods sold) x 365 days

In order to measure the operating performance extending over several periods, key performance measures are adjusted by special items, where applicable. Adjusted measures are labelled with “before special items”. A reconciliation table is available within the respective quarterly or annual report and presents the composition of special items.

Current assets (including deferred assets) - accruals - trade accounts payable - other liabilities - deferred charges

Download

All | None

Download

Related Links

Interactive Tool

FAQ

Frequently asked questions and Information on Fresenius SE & Co. KGaA

Hospital Director Sandra Henek (left) and Deputy Ward Manager Regina Ascher say thanks and farewell to Nurse Florence de Peralta (center).

Her first look at Germany on that long-ago morning was not very encouraging. “Everything here looks so gray and dismal,” Florence de Peralta remembers thinking as she landed in Frankfurt back in February 1972. The young nurse was used to the warm temperatures of her native Philippines, not the cold winters of western Europe. But she had taken a decision to pursue a new life, so she got off the plane and started building it.

(Published: August 2015)

Forty-four years later, de Peralta, now 67 and recently retired from HELIOS Hospital Hünfeld, can look back on a successful career at the hospital and the founding and raising of a family in Germany. She’s glad she came, and that she stayed, even if it wasn’t always easy.

When Florence de Peralta arrived along with five other young Philippine nurses assigned to the hospital in Hünfeld, a town of 16,000 people some 100 kilometers (60 miles) north of Frankfurt, Germany was far less multicultural than it is today. The six nurses only came because of an intergovernmental agreement that nurses from the Philippines would work in Germany to help overcome a serious nursing shortage. In total, some 3,000 Philippine nurses came between 1969 and 1973. Thousands of nurses from India and Korea were also recruited during those years.

Today, advance preparation – especially language training – is customary for newcomers to Germany, but in Florence de Peralta’s day it wasn’t thought necessary. She arrived not knowing a word of German but was still expected to start right away at the hospital, “where we communicated with hand signals,” and take language lessons later.

She soon got used to her new country, though, with the help of colleagues and many friendly local people, including some families who helped her settle in and find her way around. “I was given a very warm welcome everywhere, both from the people in Hünfeld and from the colleagues and patients in the hospital,” Florence de Peralta recalls.

Still, Hünfeld is a small town, de Peralta was away from family and friends and living in a country with a very different culture. At times, homesickness was hard to shake. Then, at a gathering of the German-Philippine Association in Mainz, just west of Frankfurt, she bumped into Arsenio, whom she had known before taking her training back home. “He wouldn’t let me go,” she jokes of the man who would become her husband and with whom she has two children, Florian and Jennifer. She and Arsenio even worked together for a time in the Hünfeld hospital.

Florence de Peralta enters retirement with mixed feelings – sorry to say goodbye to work that has given her so much satisfaction, but grateful for the memories, the friends and colleagues, not to mention the many happy years of family life. “Nursing has brought me a lot of pleasure and joy,” Florence de Peralta says. “Having some understanding and sympathy for ill people and looking after them – that has always been my passion.” And for Florence and Arsenio de Peralta, there is still a lot to look forward to – including a long trip back to the country they left behind all those years ago for their new home in Germany.

Related Links

Hospitals Health Care A day on the Neonatology

Frauke Quidde’s right hand had been almost completely severed when she was brought in to HELIOS Hospital Hildesheim. Thanks to the rapid intervention of the medical team, and her own hard work during rehabilitation, she again has good movement in the hand
Frauke Quidde’s right hand had been almost completely severed when she was brought in to HELIOS Hospital Hildesheim. Thanks to the rapid intervention of the medical team, and her own hard work during rehabilitation, she again has good movement in the hand
Frauke Quidde’s right hand had been almost completely severed when she was brought in to HELIOS Hospital Hildesheim. Thanks to the rapid intervention of the medical team, and her own hard work during rehabilitation, she again has good movement in the hand

Without the successful surgery by the medical team at HELIOS Hospital Hildesheim, life might have taken a hard turn for Frauke Quidde. She was cutting firewood on her small farm last year when her hand slipped inside a log-splitting machine and was almost completely severed at the wrist. “It was a total, absolute shock,” she recalled. “My right hand was literally hanging by threads.”

(Published: January 2016)

Every minute counted now. While waiting for emergency personnel to arrive at the farm near Braunschweig – a northern German city also known as Brunswick – Frauke Quidde had to use her left hand to hold the severed hand in place as best she could. Then she was moved into a rescue helicopter, which flew her approximately 45 kilometers (28 miles) to HELIOS Hospital Hildesheim, where a surgical team headed by Dr. Bernd Rieck was standing ready in the operating room.

The first card Frauke Quidde was able to write in the rehabilitation clinic was addressed to the medical team in Hildesheim. She penned it with her reattached right hand. Just a few months later, she was back – and busy! – on the farm.
The first card Frauke Quidde was able to write in the rehabilitation clinic was addressed to the medical team in Hildesheim. She penned it with her reattached right hand. Just a few months later, she was back – and busy! – on the farm.
The first card Frauke Quidde was able to write in the rehabilitation clinic was addressed to the medical team in Hildesheim. She penned it with her reattached right hand. Just a few months later, she was back – and busy! – on the farm.

“It was crucial to restore the blood flow as quickly as possible,” explained Dr. Rieck, Chief Physician in the hospital’s Plastic, Aesthetic and Hand Surgery Department. “Every quarter hour increases the risk of permanent damage to the hand. So we not only needed to work very precisely, but also very quickly.”

“I was very lucky, but for me it was really a medical masterpiece.”

Dr. Rieck, Resident Physician Jakob Krainski and the rest of the team decided to rejoin the blood vessels, tendons and nerves before stabilizing the bone – a reversal of the usual order. By the time blood started recirculating through the hand, “only” three hours had elapsed. “That is a phenomenally good time,” Dr. Rieck explained. “You had an old veteran like me and a young master working together at the operating table. This operation had already been performed at other hospitals, but they didn’t all do it as well. It was real teamwork.”

Just two days after the accident, Frauke Quidde could start moving her fingers, and she continued to make rapid progress during rehabilitation. Today, she is back working on the farm, doing all the things she did before: harvesting fruit, driving the tractor, and feeding the animals.

Frauke Quidde and husband Detlev, flanked by Chief Physician Dr. Bernd Rieck (left) and Resident Physician Jakob Krainsk.

“Ms. Quidde is an extraordinarily brave and determined woman,” said Jakob Krainski. “The excellent result is also attributable to her positive approach: She really supported all the therapies and gave tremendous cooperation. I’m really proud of my patient, and she should feel proud, too.”

What Frauke Quidde mostly feels, though, are a sense of gratitude and a deep appreciation that she has been able to return to her old, active life. “I’m really thankful to the doctors, the nurses and the rest of the staff in Hildesheim that I can move my hand again and drive a car, and above all that I can lead an independent life,” she said. “That’s why it was clear to me that the first card I could write from the rehabilitation clinic would be to the medical team in Hildesheim. It was just a small ‘thank you’ to the doctors and the medical staff in the hospital. I was very lucky, but for me it was really a medical masterpiece. My husband and I are unbelievably grateful.”

Fresenius is a global healthcare company headquartered in Bad Homburg v. d. Höhe, Germany. In fiscal year 2024, Fresenius generated €21.5 billion in annual revenue with over 176,000 employees (excluding Fresenius Medical Care). As a healthcare company focused on therapy, Fresenius offers system-critical products and services for leading therapies for the care of critically and chronically ill patients.

The Fresenius Group comprises the Operating Companies Fresenius Kabi and Fresenius Helios as well as the Investment Company Fresenius Medical Care.

We save and improve human lives with affordable, accessible, and innovative healthcare products and the highest quality in clinical care.

View through the camera: Cinderella Glücklich during the shooting for the video interview

A staircase, but no elevator; a high shelf or a very heavy door: Routine, minor annoyances that most people hardly notice, but potentially insurmountable problems for someone in a wheelchair. Office life constantly throws up obstacles like these, so maybe the disabled should forget about working in “ordinary” companies and limit themselves to workshops for the handicapped or similar institutions?

(Published: July 2015)

“No,” Cinderella Glücklich replies, clearly and without hesitation. Yes, she has been disabled since birth and has to spend most of the day in a wheelchair, but she is not going to let that stop her from pursuing her dream of a career in public relations or marketing.

Glücklich has been studying Journalism and Corporate Communications since 2013 in Iserlohn, Germany, and, here at Fresenius, completed an internship in Corporate Communications and Human Resources Marketing. She told us a little bit about some of the difficulties she faces in daily life and, in particular, in searching for a job.

As a disabled person, what is it like searching for a job?
Searching for a job is very difficult for me. There are a lot of bureaucratic obstacles that make it hard for handicapped people to find a job. The barriers in people’s minds are a much bigger problem, though. Many employers refused to hire me because they thought that due to my disability I wouldn’t be able to work. But it’s not like that at all: Working is very important to me, because I want to be independent.

Cinderella Glücklich blogs about her life and the challenges she faces. Cinderella wants to break down prejudices and encourage other disabled people.

Did you decide at a very young age which career you wanted to pursue?
No, after finishing school, at first I looked for some vocational training. But at the government employment center they only wanted to send me to a training center for the severely handicapped. It seemed like an endless search, but in the end I got a year-long internship in a tourist information office. I really enjoyed that, and it enabled me to complete the work experience requirement for the diploma I needed to attend a technical university. After that, it turned out to be almost as difficult to find the right technical university with wheelchair accessibility. But I am happy in Iserlohn.

Your blog about living with a disability. What is your motivation?
In my blog I report first-hand about my life with a disability. I want to break down prejudices. It is very important that people lose their fear of contact with the disabled and the whole issue of disabilities. And it makes me very happy to encourage other disabled people to live their lives in their own way and to live up to their potential.

Why did you decide to do your internship at Fresenius?
I decided to do my internship at Fresenius because I liked that the company helps sick people. And I was completely won over by the uncomplicated way everyone handled my disability, right from the start. They see me as a regular colleague, not just as “the girl in the wheelchair” – and that feels great!

“The barriers in people’s minds are the worst”

Cinderella Glücklich has been handicapped since birth. In an interview, the Fresenius intern talked about the challenges she faces in daily life and in finding a job.

Related Links

Group Overview

Contact

Fresenius SE & Co. KGaA
Else-Kröner-Str. 1
61352 Bad Homburg
Germany
T: +49 6172 608-0
pr-fre@fresenius.com

Contact

Vice President Investor Relations
Deputy Head of Investor Relations
T: +49 (0) 6172 608-5167
florian.feick@fresenius.com

Share Price

Data is delayed by 15 minutes.

Share Price Information

Event

August 06, 2025 - 01:30 pm | Bad Homburg, Germany

Webcast Q2/25 Aide Memoire Presentation Investor News Transcript Import (ICS)

Annual Report

Online Annual Report 2024

Related Links

Interactive Tool

Investor Feedback

Conference

Open dialogue is valuable for us.

You can submit your feedback quickly and easily using the link below (anonymously if you prefer). You will be redirected to QuantiFire which conducts this survey in own controllership.

QuantiFire's privacy policy can be found at the bottom of the page linked to.

Submit Feedback

Fresenius Q2/25: Guidance raised - Resilient business continues to deliver consistent performance

Q2/2025: Ongoing strong revenue and EPS growth, guidance for organic revenue growth raised

Group revenue¹ at €5,571 million with organic growth of 5%^1,2 driven by consistent delivery across the core businesses Fresenius Kabi and Fresenius Helios as well as ongoing execution of #FutureFresenius.
Group EBIT¹ broadly stable³ in constant currency at €654 million impacted by the headwinds from ceased energy relief payments at Helios Germany and the loss of the volume-based procurement tender for the nutrition product Ketosteril in China at Fresenius Kabi; Group EBIT margin¹ at 11.7%.
Net income^1,4 with strong 8%³ growth in constant currency to €412 million outpacing revenue growth.
EPS^1,4 rose by strong 8%³ in constant currency to €0.73 demonstrating continued bottom-line delivery based on operating strength and significantly decreased interest expenses.
Net debt/EBITDA ratio at 3.1x^1,5 driven by resumed dividend payment in Q2/25.
Pro rata sale of Fresenius Medical Care shares to maintain current stake in response to the announced Fresenius Medical Care share buyback program.

¹ Before special items
² Organic growth rate adjusted for accounting effects related to Argentina hyperinflation
³ Growth rate adjusted for Argentina hyperinflation
⁴ Excluding Fresenius Medical Care
⁵ At average exchange rates for both net debt and EBITDA; pro forma closed acquisitions/divestitures, including lease liabilities, including Fresenius Medical Care dividend, net debt adjusted for the valuation effect of the equity-neutral exchangeable bond

Q2/25 Results

Q2/2025 Webcast

Documents

Q2/25 Aide Memoire (PDF) Q2/25 Investor News (PDF) Q2/25 Key Figures (XLSX) Q2/25 Presentation (PDF) Half-year Financial Report H1/2025 (PDF) Q2/25 Transcript (PDF)

Selected Key Figures Q2/2025

GROUP REVENUE ¹

€ 5571 m

+ 5% ²

Q2/24: €5,414 m

GROUP EBIT ¹

€ 654 m

+0% ³

Q2/24: €660 m

NET INCOME ^{1, 4}

€ 412 m

+8% ³

Q2/24: €388 m

EPS ^{1, 4}

€ 0.73

+8% ³

Q2/24: €0.69

¹ Before special items

² Organic growth rate adjusted for accounting effects related to Argentina hyperinflation

³ Growth rate at constant currency (cc) and adjusted for Argentina hyperinflation

⁴ Excluding Fresenius Medical Care

Revenue by business segment

€ in millions	Q2/25	Q2/24	Growth at actual rates	Growth at constant rates	Organic growth¹	Acquisitions/Divestitures	% of total revenue
Fresenius Kabi	2,111	2,101	0%	5%	6%¹	-1%	38%
Fresenius Helios	3,370	3,230	4%	5%	5%	0%	60%
Total	5,571	5,414	3%	5%	5%	0%	100%²

¹ Organic growth rate adjusted for accounting effects related to Argentina hyperinflation
² Remaining 2% Corporate/Other revenue
Before special items

#FutureFresenius is clearly paying off:

Q2/25: Guidance raised – Resilient business continues to deliver consistent performance

Ongoing EPS and revenue growth reflecting good operational progress and continued execution of #FutureFresenius strategy
Guidance raised: we are raising our full-year guidance for organic revenue growth to 5-7%
Strong bottom-line performance continues with 8% Core EPS growth driven by Fresenius Kabi and Fresenius Helios and significant decrease in interest expense
Fresenius Kabi continues to enhance profitability with strong 16.4% EBIT margin and execution of launch pipeline for both IV Generics and Biosimilars progressing well
Fresenius Helios with solid organic revenue growth; Helios Performance Program advancing

View the full Q2/25 update in the Financial Results section

Read more about our company strategy!

FRESENIUS SE & CO. KGaA

Event

August 06, 2025 - 01:30 pm | Bad Homburg, Germany

Webcast Q2/25 Aide Memoire Presentation Investor News Transcript Import (ICS)

“Fresenius has demonstrated a resilient and consistent performance in the first half of 2025, with another quarter of strong momentum reflected by 8% Core EPS growth. Fresenius Kabi and Fresenius Helios continue to deliver strong results despite macroeconomic challenges, thanks to our focused strategy and disciplined execution. This performance enables us to raise our guidance, increasing our full-year expectations for revenue growth to between 5% and 7%. #FutureFresenius is paying off. Our ambitions remain unchanged: Our current strategy phase Rejuvenate will focus on organic growth through disciplined capital allocation - upgrading our core, and scaling our platforms to enhance performance further. We are committed to delivering profitable growth through targeted investments in health and digital innovation, which together will create and enhance value for our stakeholders.”

Michael Sen, Chairman of the Management Board

More information

Q2 2025 Results

Key links to dive deeper into Fresenius’ Q2 2025 results and more!

Financial Results

Resilient business continues to deliver consistent performance!

Outlook

Guidance raised: Performance enables us to increase our full-year expectations for revenue growth to between 5% and 7%.

Quarterly Report

Discover our Q2/25 Financial Report and more here!

Goals & Strategy

#CommittedToLife: The health and well-being of our patients is Fresenius' top priority. Find out more about our corporate strategy!

Investor Feedback

Open dialogue is valuable for us.

You can submit your feedback quickly and easily using the link below (anonymously if you prefer).

You will be redirected to QuantiFire which conducts this survey in own controllership.

Submit Feedback

News

Fresenius Q2/25: Guidance raised - Resilient business continues to deliver consistent performance

Fresenius Q2/25: Guidance raised - Resilient business continues to deliver consistent performance

Michael Sen, CEO of Fresenius: “Fresenius has demonstrated a resilient and consistent performance in the first half of 2025, with another quarter of strong momentum reflected by 8% Core EPS growth. Fresenius Kabi and Fresenius Helios continue to deliver strong results despite macroeconomic challenges, thanks to our focused strategy and disciplined execution."

August 06, 2025 · Fresenius
Brief News

Fresenius announces licensing agreement with Polpharma Biologics to commercialize a proposed vedolizumab biosimilar candidate

Fresenius Kabi, part of the global healthcare company Fresenius, has entered a licensing agreement with Polpharma Biologics S.A., a developer and manufacturer of biosimilar products, based in Poland. Under the agreement, Fresenius Kabi will exclusively commercialize Polpharma Biologics’ vedolizumab biosimilar candidate PB016 globally, except the Middle East and North Africa, pending approval by respective regulatory authorities. PB016 is a biosimilar candidate to Entyvio®*, an integrin receptor antagonist used in the treatment of moderately to severely active ulcerative colitis and Crohn’s disease. “Today marks a significant milestone in our journey to provide patients with access to affordable, high-quality biosimilar treatments,” said Dr. Sang-Jin Pak, President Biopharma at Fresenius Kabi. “The in-licensing of PB016 from Polpharma Biologics underscores our commitment to expanding our autoimmune biosimilars portfolio and addressing the unmet needs of patients with chronic inflammatory diseases.” This agreement builds on Fresenius Kabi’s successful track record in the biosimilars market, including the recent FDA and EC approvals of its denosumab and ustekinumab biosimilars. This milestone underscores Fresenius Kabi’s commitment to broadening access to essential, high-quality biosimilar therapies. Through this agreement, Fresenius is strengthening its (Bio)Pharma platform, which is a key pillar of the #FutureFresenius strategy. *Entyvio® is a registered trademark of Takeda.

August 05, 2025 · Fresenius Kabi

Brief News

Fresenius Receives European Commission Approval for Denosumab Biosimilars

Fresenius announced today that the European Commission has granted approval for their denosumab biosimilars Conexxence®* and Bomyntra®* in Europe. The two approvals cover all indications of the reference products including osteoporosis in postmenopausal women and at-risk men, treatment-related bone loss, prevention of skeletal complications from cancer metastasis to bone, and giant cell tumor of bone. This milestone marks a significant advancement in Fresenius Kabi’s mission to expand access to high-quality biosimilar therapies. It also reinforces the business’ commitment to strengthening its Biopharma platform, a key pillar of the #FutureFresenius strategy. *Conexxence and *Bomyntra are registered trademarks of Fresenius Kabi Deutschland GmbH in selected countries.

July 23, 2025 · Fresenius Kabi
Brief News

Fresenius publishes Aide Memoire for the upcoming Q2 2025 reporting

Fresenius has published the Aide Memoire ahead of its Q2 2025 financial reporting. The Aide Memoire is a summary of relevant information that Fresenius has previously communicated previously to the capital market or otherwise made publicly available . The document may prove helpful in assessing Fresenius' financial performance ahead of the publication of quarterly results.The Q2 2025 Aide Memoire is now available on the Fresenius Investor Relations website. The results of the second quarter and first half of 2025 of Fresenius SE & Co. KGaA will be published on 6 August 2025. The Quiet Period will start on 24 July 2025.

July 16, 2025 · Fresenius

Brief News

Fresenius expands Biopharma Portfolio in the U.S. with Denosumab Biosimilars availability

Fresenius announced today that its Operating Company Fresenius Kabi has introduced two new biosimilars in the U.S., Conexxence®(1) (denosumab-bnht) and Bomyntra®(2) (denosumab-bnht).These denosumab biosimilars are approved by the FDA for all indications of the reference products, Prolia®(3) (denosumab) and Xgeva®(4) (denosumab), respectively. The biological medicines are used for the treatment of osteoporosis and other bone-related conditions.This milestone represents Fresenius’ fifth and sixth biosimilars available in the U.S. It is a showcase of the company’s efforts to drive patient access to high-quality biological medicines. Earlier this year, Fresenius announced a global settlement with Amgen concerning its denosumab biosimilars. The company thereby continues the growth path of its BioPharma platform in line with #FutureFresenius.Conexxence®(1) and Bomyntra®(2) are registered trademarks of Fresenius Kabi Deutschland GmbH in selected countries. Prolia®(3) and Xgeva®(4) are registered trademarks of Amgen Inc.Read the full press release here.

July 03, 2025 · Fresenius
Brief News

Anke Schmidt appointed Head of Corporate Communications at Fresenius

Fresenius announced today that the internationally experienced and highly recognized communications expert Anke Schmidt has been appointed Head of Corporate Communications at Fresenius, effective June 1, 2025. She will succeed Dennis Hofmann, who headed the global communications function at Fresenius since September 2022 and has decided to leave the company on his own request to pursue new opportunities. Anke Schmidt joins Fresenius from Beiersdorf, where she has served as Global Vice President Corporate Communications & Government Relations since 2020. Prior to that, she held various senior roles in Communications, Government Relations, and Human Resources at BASF over a period of 24 years, both in Germany and abroad.

May 27, 2025 · Fresenius

Brief News

Denosumab CHMP Positive Opinion

Fresenius announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion for its denosumab biosimilar candidates for the treatment of osteoporosis and other bone-related conditions. The biosimilars are recommended for approval for all indications of the reference products 1Prolia® (denosumab) and 2Xgeva® (denosumab) from AMGEN. The CHMP positive opinion marks an important step in Fresenius Kabi's efforts to enhance patient access to biosimilar products and expand its capabilities and portfolio in biosimilars development. Developing the company's Biopharma platform is a key element of #FutureFresenius. 1Prolia® and 2Xgeva® are registered trademarks of Amgen Inc.

May 27, 2025 · Fresenius Kabi
Brief News

Fresenius expands its line of Epinephrine injectables in the U.S.

Fresenius today announced that its operating company, Fresenius Kabi, is now offering Epinephrine Injection, USP, in 30 mg per 30 mL multi-dose vials in the United States. Following the introduction of the first generic version of Epinephrine, USP, in a 1 mg per mL vial for U.S. customers in December 2024, the product launch expands Fresenius’ offerings of Epinephrine Injection. Epinephrine Injection 30 mg per 30 mL is a prescription medicine used for emergency treatment of allergic reactions (Type 1), including anaphylaxis, in adults and pediatric patients and to increase mean arterial blood pressure in adult patients with hypotension associated with septic shock. In line with #FutureFresenius, Fresenius Kabi has invested more than $1 billion to expand and modernize advanced U.S. pharmaceutical production and distribution facilities. Epinephrine Injection is manufactured in the U.S., reflecting the company’s commitment to domestic production. More than 70% of the pharmaceuticals that Fresenius Kabi sells to U.S. customers are formulated, filled and packaged in the U.S.

May 20, 2025 · Fresenius Kabi

Fresenius Q1/25: Strong start to 2025 – #FutureFresenius REJUVENATE phase kicked-off with excellent momentum

Fresenius Q1/25: Strong start to 2025 – #FutureFresenius REJUVENATE phase kicked-off with excellent momentum

May 07, 2025 · Fresenius
Brief News

Fresenius makes progress on streamlining its production network

Fresenius continues reducing complexity and optimizing utilization in the production network of its Operating Company Fresenius Kabi in line with its Vision 2026 and #FutureFresenius: Today, Fresenius Kabi and EMS have signed an agreement to transfer the ownership of Fresenius Kabi's production site in Anápolis, Brazil, to EMS. The multinational pharmaceutical company has a strong presence in Latin America and will take over the generic injectables production plant, the development center, and the warehouse as well as full staff and will continue production. The transaction is subject to customary closing conditions, including merger approval.

April 09, 2025 · Fresenius Kabi

Brief News

Fresenius completes divestment of Vamed’s international project business

Fresenius has completed the divestment of Vamed’s international project business to Worldwide Hospitals Group (WWH), that was announced in February 2025. The divestment is part of Fresenius’ structured exit from its Investment Company Vamed and enables Fresenius to further increase focus and management capacity on the ongoing progress of its core businesses Fresenius Kabi and Fresenius Helios, in line with #FutureFresenius.

April 01, 2025 · Fresenius
Brief News

Fresenius Receives FDA approval for their Denosumab Biosimilars and Secures Global Settlement

Fresenius today announced that the Biologics License Application (BLA) for the denosumab biosimilars Conexxence®** (denosumab-bnht) and Bomyntra®** (denosumab-bnht) of its operating company Fresenius Kabi has been approved by the U.S. Food and Drug Administration (FDA). The denosumab biosimilars are approved for all indications of the reference products Prolia®* (denosumab) and Xgeva®* (denosumab), respectively. Additionally, Fresenius’ operating company has reached a global settlement with Amgen, allowing the launch of these biosimilars in the US from mid-2025 and in Europe later end of November 2025 subject to regulatory approval. The FDA approval and the global settlement agreement with Amgen are the latest developments in Fresenius’ continuing commitment to improving patient access to high-quality biological products through expanding its biosimilars development capabilities and product portfolio. Growing the company's (Bio)Pharma platform is a substantial cornerstone of #FutureFresenius. *Prolia® and Xgeva®* are registered trademarks of Amgen Inc. **Conexxence® and **Bomyntra® are registered trademarks of Fresenius Kabi Deutschland in selected countries. Read the full press release here. Please click to see full Prescribing Information for Conexxence®. Please click to see full Prescribing Information for Bomyntra®.

March 26, 2025 · Fresenius Kabi

Brief News

Fresenius publishes 2024 Annual Report: #FutureFresenius makes the company more innovative, more focused and more efficient

Today, Fresenius published its 2024 Annual Report. As already announced in February, the healthcare group grew profitably in the past year and achieved its outlook, which was raised twice, through consistently good business performance. Group revenue before special items increased to €21.5 billion, with organic growth of 8%. Fresenius was also able to reduce net debt by €2 billion in 2024. “Our #FutureFresenius program, which we launched at the end of 2022, is having an impact. The “new” Fresenius is much more focused. We are concentrating on Fresenius Kabi and Fresenius Helios. These are growing profitably and under their own steam,” said Michael Sen, Chairman of the Management Board of Fresenius. “Growth, higher margins, more cash, lower debt – all this has created value: From the beginning of October 2022, when we prepared the ReSet, until February 28, 2025, the share price rose by 76%.” For the first time, the Annual Report includes a sustainability report in accordance with the European Sustainability Reporting Standards (ESRS). This replaces the Non-financial Report of previous Annual Reports and expands and supplements reporting topics and details. In addition, the ESRS report, like the financial report, is audited externally. The 2024 Annual Report is available in German and English as a PDF file and as an online version. Further publication and event dates for 2025: · 04/24/2025: Publication of Sustainability Highlights Magazine · 05/07/2025: Publication of the financial results for Q1 2025 · 05/23/2025: Annual General Meeting · 08/06/2025: Publication of the financial results for Q2 2025 · 11/05/2025: Publication of the financial results for Q3 2025

March 26, 2025 · Fresenius
Fresenius completes sale of shares in Fresenius Medical Care AG

Fresenius completes sale of shares in Fresenius Medical Care AG

Michael Sen, CEO and Chairman of the Fresenius Management Board said: "This pivotal milestone of selling a stake in Fresenius Medical Care marks another significant step in #FutureFresenius, providing us with enhanced strategic flexibility to further strengthen our growth platforms while setting the basis for long-term profitable growth as we prepare for the next phase, REJUVENATE.

March 04, 2025 · Fresenius
Fresenius announces its intention to reduce its stake in Fresenius Medical Care AG to 25% plus one share

Fresenius announces its intention to reduce its stake in Fresenius Medical Care AG to 25% plus one share

Fresenius intends to sell approximately 10.5 million shares of FME (the "Shares"), equivalent to approximately 3.6% of FME's issued share capital, by way of an accelerated bookbuilding procedure (the "Equity Offering").

March 03, 2025 · Fresenius
Brief News

Continuing Biopharma Growth with U.S. and EU Launch of Ustekinumab Biosimilar

Fresenius announced today that its Operating Company Fresenius Kabi’s ustekinumab biosimilar Otulfi® (ustekinumab-aauz), developed by Formycon AG, is now available in the United States and European Union. Otulfi® is an ustekinumab biosimilar for the reference product Stelara® (ustekinumab). In February 2023, Fresenius Kabi and Formycon entered a global commercialization partnership for the ustekinumab biosimilar covering key global markets. In September 2024, U.S. FDA and EC approval for both subcutaneous and intravenous formulations was received. Otulfi® is indicated for the treatment of Crohn’s disease, ulcerative colitis, moderate to severe plaque psoriasis and active psoriatic arthritis in the U.S. Being Fresenius’ fourth biosimilar on the market, the company continues the growth path of its BioPharma platform in line with #FutureFresenius.

March 03, 2025 · Fresenius Kabi

Fresenius FY/24: Strong Fourth Quarter concludes successful Fiscal Year; Fresenius moving to next level of performance with #FutureFresenius Rejuvenate phase

Fresenius FY/24: Strong Fourth Quarter concludes successful Fiscal Year; Fresenius moving to next level of performance with #FutureFresenius Rejuvenate phase

February 26, 2025 · Fresenius
Fresenius reaches agreement to exit Vamed’s international project business ahead of schedule

Fresenius reaches agreement to exit Vamed’s international project business ahead of schedule

Fresenius entered an agreement with Worldwide Hospital Group (WWH) to fully divest Vamed’s international project business (Health Tech Engineering, HTE). In May 2024, Fresenius originally announced a gradual wind-down of the HTE project business, largely to be completed by 2026, as part of Fresenius’ structured exit from its Investment Company Vamed.

February 03, 2025 · Fresenius

All News Open Order Serivce Disclaimer

Social Media

Details Figures

Please visit Fresenius Investor Relations on LinkedIn!

Go to LinkedIn

Go to Twitter

Contact

Senior Vice President Investor Relations
Head of Investor Relations
T: +49 (0) 6172 608-97033
nick.stone@fresenius.com

Share Price

Data is delayed by 15 minutes.

Share Price Information

Related Links

Interactive Tool Total Return Calculator

FAQ

Shares and dividends Annual General Meeting

The Annual General Meeting of Fresenius SE & Co. KGaA took place on May 23, 2025, at the Congress Center, Messe Frankfurt, Ludwig-Erhard-Anlage 1, 60327 Frankfurt am Main, Germany.

All members of the Management Board and the Supervisory Board attended the entire Annual General Meeting.

Internet broadcast

The opening of the Annual General Meeting by the Chairman of the Supervisory Board, Wolfgang Kirsch, and the report by the Chairman of the Management Board, Michael Sen, were broadcast publicly.

Speech of CEO Michael Sen

Watch replay Speech of CEO (PDF, 172KB) Presentation (PDF, 8.84MB)

Credit Suisse – 10th Annual December Bus Tour

“I was very lucky, but for me it was really a medical masterpiece.”

We save and improve human lives with affordable, accessible, and innovative healthcare products and the highest quality in clinical care.

Fresenius Q2/25: Guidance raised - Resilient business continues to deliver consistent performance

Selected Key Figures Q2/2025

Archive

#FutureFresenius is clearly paying off:

Investor Feedback

News

Fresenius Q2/25: Guidance raised - Resilient business continues to deliver consistent performance

Fresenius announces licensing agreement with Polpharma Biologics to commercialize a proposed vedolizumab biosimilar candidate

Fresenius Receives European Commission Approval for Denosumab Biosimilars

Fresenius publishes Aide Memoire for the upcoming Q2 2025 reporting

Fresenius expands Biopharma Portfolio in the U.S. with Denosumab Biosimilars availability

Anke Schmidt appointed Head of Corporate Communications at Fresenius

Denosumab CHMP Positive Opinion

Fresenius expands its line of Epinephrine injectables in the U.S.

Fresenius Q1/25: Strong start to 2025 – #FutureFresenius REJUVENATE phase kicked-off with excellent momentum

Fresenius makes progress on streamlining its production network

Fresenius completes divestment of Vamed’s international project business

Fresenius Receives FDA approval for their Denosumab Biosimilars and Secures Global Settlement

Fresenius publishes 2024 Annual Report: #FutureFresenius makes the company more innovative, more focused and more efficient

Fresenius completes sale of shares in Fresenius Medical Care AG

Fresenius announces its intention to reduce its stake in Fresenius Medical Care AG to 25% plus one share

Continuing Biopharma Growth with U.S. and EU Launch of Ustekinumab Biosimilar

Fresenius FY/24: Strong Fourth Quarter concludes successful Fiscal Year; Fresenius moving to next level of performance with #FutureFresenius Rejuvenate phase

Fresenius reaches agreement to exit Vamed’s international project business ahead of schedule

Share

Social Media

Information on the Annual General Meeting on May 23, 2025

Countermotions and election proposals

Total number of shares and of voting rights at the time of the convocation (Section 124 a sentence 1 no. 4 of the German Stock Corporation Act)

Archive

Countermotions

Countermotions

Countermotions and election proposals

Total number of shares and of voting rights at the time of the convocation (Section 124 a sentence 1 no. 4 of the German Stock Corporation Act)

Counter motions

Total number of shares and of voting rights at the time of the convocation (Section 124 a sentence 1 no. 4 of the German Stock Corporation Act)

Counter motions

Total number of shares and of voting rights at the time of the convocation (Section 124 a sentence 1 no. 4 of the German Stock Corporation Act)

Counter motions

Total number of shares and of voting rights at the time of the convocation (Section 124 a sentence 1 no. 4 of the German Stock Corporation Act)

Further information on the AGM 2018

Further information on the AGM 2017

Further information on the AGM 2016

Further information on the AGM 2015

Counter motions